In addition, vitexin has shown inhibition against nasopharyngeal carcinoma, colorectal carcinoma, epithelial ovarian cancer, and leukemia by targeting NF-κB, JNK, ERK, and RAS/RAF pathways, respectively [39–42]. Here, NFKB1 is linked to nasopharyngeal carcinoma.